Introduction {#S0001}
============

With continuously rising incidence and mortality, colorectal cancer (CRC) has become the second most common cancer in the world and the third leading cause of cancer deaths in 2018.[@CIT0001] The 5-year relative survival ranges from over 90% in patients with stage I disease to around 10% in patients with stage IV disease.[@CIT0002] However, with the introduction of targeted therapy over the past two decades, the life expectancy of patients with metastatic CRC (mCRC) has improved significantly from 12 to 30--40 months in various studies.

Regorafenib is an oral multikinase inhibitor blocking activity of angiogenic, stromal and oncogenic protein kinases.[@CIT0003],[@CIT0005] Regorafenib has been approved in heavily pre-treated mCRC patients based on the results of a randomized double-blind placebo-controlled Phase III trial CORRECT (NCT01103323) that showed an OS benefit of regorafenib monotherapy over the best supportive care alone.[@CIT0006] The previous treatment usually included chemotherapy regimens with fluoropyrimidine, oxaliplatin, irinotecan, combined with targeted antiangiogenic (anti-VEGF) agents and, in wild-type RAS tumors, anti-EGFR therapy.[@CIT0006]

The present study is based on a substantial expansion of the initial cohort of 148 regorafenib-treated patients from the Czech national registry.[@CIT0007] The objective of the study was to analyze treatment outcomes and associated prognostic factors in mCRC patients treated with regorafenib.

Materials and Methods {#S0002}
=====================

Patients, Data Source, and Inclusion Criteria {#S0002-S2001}
---------------------------------------------

The national CORECT registry was used as a data source for the present analysis. The CORECT registry was a post-marketing database gathering anonymized data of CRC patients treated with targeted agents in the Czech Republic containing data on baseline characteristics, course of treatment, and outcomes.

The data entries were updated twice a year. The therapy with targeted agents in the Czech Republic outside of clinical trials is reimbursed only in comprehensive cancer centers, and the registry has been estimated to provide data on approximately 95% of all patients treated with targeted therapy for mCRC in these centers.[@CIT0008] There are 17 comprehensive cancer centers and all have contributed to the database. The contribution to the patient-based database was mandatory for regorafenib reimbursed by public health insurance.[@CIT0007] There was no external monitoring of the data. The cohort for analysis included all patients with colorectal adenocarcinoma and valid data in the registry (including baseline patient characteristics, treatment, and follow-up data) who received regorafenib from 2011 to 2017. The data cut-off was October 2, 2017.

Treatment {#S0002-S2002}
---------

Regorafenib (Stivarga, Bayer Pharma AG, Berlin, Germany) was administered according to the registration label to patients with mCRC previously treated with fluoropyrimidine, oxaliplatin, irinotecan, anti-VEGF therapy, and, in wild-type RAS tumors, also anti-EGFR therapy. The recommended initial dose was 160 mg given as four 40 mg tablets orally daily for the first 21 days of a 28-day cycle. The treatment continued until disease progression or unacceptable toxicity. Dose reductions were at the discretion of the treating physician. The treatment response was evaluated by computed tomography (CT) according to the RECIST 1.1 criteria every 3 months.[@CIT0009]

Statistical Analysis {#S0002-S2003}
--------------------

Progression-free survival (PFS) was defined as the time from the regorafenib treatment initiation to the date of the first documented progression or death due to any cause. Overall survival (OS) was defined as the time from regorafenib treatment initiation to the date of death due to any cause. Response rates were calculated for patients with terminated treatment.

Descriptive statistics and frequency tables were used to characterize the sample data set. PFS and OS were estimated using Kaplan-Meier method and all point estimates include 95% confidence intervals (95% CI). Multivariable Cox proportional hazards model was used to evaluate independent effects of potential prognostic factors on the PFS and OS. Statistical significance of hazard ratios was assessed by Wald test. All statistical tests were performed at a significance level of α = 0.05. Power analysis was not performed -- this analysis is a retrospective evaluation of the registry data and all results must be interpreted with respect to the confidence intervals.

Results {#S0003}
=======

Patient Characteristics {#S0003-S2001}
-----------------------

In total, 555 patients treated with regorafenib between 2011 and 2017 were identified and included in the present analysis. The majority were male (n=360, 64.9%) and the median age at diagnosis was 61.7 years. The primary tumor localization was the left colon including rectum in 420 patients (75.7%) and the right colon in 110 patients (19.8%). Information on primary tumor localization was missing or there were multiple colon primary tumors in 4.5% of cases. Most patients (n=343, 61.8%) had had synchronous distant metastases at diagnosis, and the prevailing histology type was adenocarcinoma (n=530, 95.5%). Mutations of RAS gene were detected in 258 cases (46.5%). When initiating treatment with regorafenib, all patients were fully active or had only slightly reduced physical activity with ECOG performance status 0--1, as required in the reimbursement conditions for the drug. Only 80 (14.4%) patients received regorafenib within 18 months of diagnosis of metastatic disease Baseline characteristics related to regorafenib treatment are summarized in [Table 1](#T0001){ref-type="table"}.Table 1Baseline Patient CharacteristicsParameterSubgroupValueGender, n (%)Women195 (35.1)Men360 (64.9)Age at diagnosis yearsMedian (range)61.7 (24.1--81.3)Age at regorafenib initiation yearsMedian (range)64.9 (26.3--83.7)Site of primary tumor, n (%)Left colon or rectum420 (75.7)Right colon or transversum110 (19.8)Colon without side specification25 (4.5)Distant metastasis at diagnosis, n (%)Absent (M0)212 (38.2)Present (M1)343 (61.8)Primary tumor histology, n (%)Adenocarcinoma530 (95.5)Mucinous adenocarcinoma15 (2.7)Signet ring cell carcinoma4 (0.7)Other6 (1.1)RAS status, n (%)Mutated258 (46.5)Wild type^a^280 (50.5)Not tested/not known17 (3.1)BRAF status, n (%)Mutated23 (4.1)Wild type132 (23.8)Not tested/not known400 (72.1)Prior therapies^b^, n (%)Bevacizumab495 (89.2)Cetuximab131 (23.6)Panitumumab154 (27.7)Aflibercept90 (16.2)Trifluridine/tipiracil10 (1.8)Time from diagnosis of CRC to regorafenib treatment initiation (months)Median (range)34.5 (5.1--168.4)BMI at regorafenib treatment initiation^c^, n (%)≤ 25 kg/m^2^179 (35.6)\> 25 kg/m^2^324 (64.4)Site of metastases at regorafenib treatment initiation^d^, n (%)Liver only90 (16.5)Other organs ± liver454 (83.5)ECOG PS at regorafenib treatment initiation, n (%)PS 0187 (33.7)PS 1368 (66.3)Line of regorafenib treatment, n (%)2nd line39 (7.0)3rd line333 (60.0)4th line134 (24.1)≥5th line49 (8.8)Initial dose of regorafenib, n (%)160 mg463 (83.6)120 mg52 (9.4)80 mg26 (4.7)Other or not specified14 (2.5)[^1][^2]

Most patients were treated with an initial dose of 160 mg daily (n = 463; 83.6%). The median treatment duration was 2.7 months (5--95th percentile range 0.4--8.6 months).

Patients treated with the full initial dose of regorafenib were more likely to have liver-only metastatic disease (17.9 vs 7.7%, *p*=0.03) and body-mass index \> 25 kg/m^2^ (66.9 vs 45.8%, *p*=0.001) compared to those with a reduced initial dose, respectively. There were no significant differences in other baseline parameters.

The median follow-up for surviving patients was 5.4 months (0.1--38.9). At the time of data cut-off, 472 (85.0%) patients had discontinued regorafenib therapy and disease progression or death was recorded for 339 (71.8%) patients.

Outcomes {#S0003-S2002}
--------

The median PFS was 3.5 months (95% CI 3.2--3.7 months). However, the result also reflects the recommended 3-month intervals for tumor assessment by imaging. The relative 3-month and 6-month PFS rates were 56.4% (95% CI 52.0--60.8%) and 24.5% (95% CI 20.5--28.5%), respectively ([Figure 1](#F0001){ref-type="fig"}).Figure 1Progression-free (**A**) and overall (**B**) survival from regorafenib treatment initiation.

The median OS reached 9.3 (95% CI 8.3--10.3) months, with 3-month and 6-months OS rates of 87.0% (95% CI 84.0--90.0%) and 67.7% (95% CI 63.4--72.1%), respectively ([Figure 1](#F0001){ref-type="fig"}).

By the data cut-off date, 472 patients (85%) have completed treatment with regorafenib and were evaluable for treatment response evaluation. The overall response rate (ORR) was 2.8% (13/472 patients), and the disease control rate was 30.3% (143/472 patients).

The main cause of treatment discontinuation in the whole cohort of 555 treated patients was radiological or clinical disease progression (n = 389; 70.1%). Treatment was discontinued for adverse events related to regorafenib in 21 patients (3.9%), and for other reasons including loss of follow-up and patient decision in 62 patients (11.1%). At the data cut-off date, 83 patients (15.0%) continued with regorafenib treatment.

Prognostic Factors {#S0003-S2003}
------------------

Multivariable analysis revealed that female gender, longer time from diagnosis of metastatic disease, M0 stage at diagnosis, and ECOG PS 0 were associated with longer PFS, while higher BMI, longer time from diagnosis of metastatic disease, and ECOG PS of 0 were associated with longer OS. Age, tumor sidedness, site of metastases at regorafenib therapy initiation, and RAS status were not associated with outcome of regorafenib therapy ([Table 2](#T0002){ref-type="table"}).Table 2Progression-Free and Overall Survival Results -- Multivariable Cox-Proportional Hazards ModelVariableCategorynProgression-Free SurvivalOverall SurvivalHRWald Test *p*-valueHRWald Test *p*-value(95% CI)(95% CI)GenderFemale1661.00-1.00-Male3101.26 (1.01--1.57)0.0421.15 (0.87--1.51)0.331Age at treatment initiation\< 60 years1351.00-1.00-≥ 60 years3410.96 (0.77--1.21)0.7360.98 (0.74--1.30)0.907BMI at treatment initiation≤ 25 kg/m^2^1731.00-1.00-\> 25 kg/m^2^3030.82 (0.65--1.02)0.0740.56 (0.43--0.74)\< 0.001Localization of primary tumourLeft colon (including rectum)3731.00-1.00-Right colon1031.21 (0.93--1.56)0.1511.12 (0.82--1.53)0.483Time from diagnosis to treatment initiation\< 18 months741.00-1.00-≥ 18 months4020.58 (0.43--0.78)\< 0.0010.45 (0.31--0.63)\< 0.001Distant metastasis at diagnosisAbsent (M0)1781.00-1.00-Present (M1)2981.38 (1.10--1.74)0.0061.30 (0.97--1.74)0.079Site of metastases at treatment initiationLiver metastases only801.00-1.00-Liver and other organs/extrahepatic metastases only3960.91 (0.68--1.20)0.4951.03 (0.72--1.48)0.858ECOG PS at treatment initiationPS 01691.00-1.00-PS 13071.26 (1.01--1.57)0.0391.80 (1.36--2.39)\< 0.001RAS statusMutated2311.00-1.00-Wild type2450.96 (0.78--1.18)0.6811.05 (0.81--1.37)0.704[^3]

For Multivariable Cox proportional hazards model, Schoenfeld residuals were used to check the proportional hazards assumption, while examining influential observations or outliers was performed by deviance residuals. Concordance (C-index) in case of progression-free survival model was 0.604 (95% CI: 0.573--0.635), C-index for overall survival was 0.662 (95% CI: 0.625--0.699).

Toxicity {#S0003-S2004}
--------

An adverse event due to treatment was the reason for treatment discontinuation in 21 (4.4%) patients. Grade 3 or higher adverse events related to treatment were recorded in 25 patients (4.5%), including hand-foot syndrome/skin reaction in 5 (0.9%) patients, fatigue in 4 (0.7%) patients, diarrhoea in 5 (0.9%) patients, hypertension in 2 (0.4%) patients, and other in 18 (3.2%) patients.

Discussion {#S0004}
==========

The present analysis of retrospective data of a national registry confirms the efficacy of regorafenib in a heavily pre-treated population of mCRC patients refractory to other systemic treatments. The observed survival in this expanded cohort of patients treated with regorafenib monotherapy was superior to OS outcomes in two prospective randomized placebo-controlled trials that led to registration of regorafenib[@CIT0006],[@CIT0010] as well as to the outcomes reported in subsequent single arm open label studies.[@CIT0011],[@CIT0012] The better outcomes in the present group of patients might be attributable to patient selection and more favorable baseline characteristics, in particular longer time from diagnosis to regorafenib initiation compared to the patients enrolled in the prospective trials. Nevertheless, a meta-analysis of retrospective studies has confirmed the efficacy results from randomized and other prospective studies, yielding a median OS of 7.3 months.[@CIT0013]

The fact that only a minority of patients treated with third-line agents for mCRC including regorafenib and trifluridine-tipiracil respond to therapy has spurred the search for a clinically useful prognostic index to identify patients with higher likelihood of benefit. The ColonLife nomogram based on the presence of primary tumor, lactate dehydrogenase level, performance status, and peritoneal involvement, has been validated in this setting and there are other sets of variables that may provide a tool for treatment individualization.[@CIT0011],[@CIT0014],[@CIT0015] In the REBECCA study based on real-life data inferior survival was associated with poor performance status and short time from initial diagnosis of metastases to the start of regorafenib, in agreement with the present data. The French group also reported reduced initial regorafenib dosage, \>3 metastatic sites, presence of liver metastases, and KRAS mutations as adverse factors for survival.[@CIT0011] Grell et al^15^ have added inflammatory biomarkers including baseline white blood cell count and C-reactive protein concentration to increase the predictive strength of an index based on clinical parameters.

Interestingly, progressive sarcopenia has been associated with regorafenib treatment in a small study by Huemer et al.[@CIT0016] While requiring further validation and expansion this observation suggests that patients with sarcopenia should be considered for alternative therapies such as trifluridine-tipiracil or supportive care only. BMI \>25 was associated with substantially better OS in the present cohort and there are data showing that low BMI is associated with sarcopenia.[@CIT0017],[@CIT0018]

A hypothesis about different prognosis of CRC tumors associated with the distinct genetic profiles as determined by primary site (proximal vs distal colon and rectum) has been re-appearing in the literature since early the 1990s.[@CIT0019],[@CIT0023] Although this association was not confirmed in the present multivariable analysis, it is worth noting that gender, which has been shown to correlate with frequency of proximal versus distal CRC remained an independent indicator of the outcome in multivariable analysis of the present cohort.[@CIT0020],[@CIT0022] Conflicting accounts of gender impacting outcomes of CRC treatment can be encountered in the literature. Some studies failed to demonstrate the prognostic value of gender in CRC patients,[@CIT0024] while others report worse outcomes in females with right-sided tumors.[@CIT0022],[@CIT0025] Nevertheless, large meta-analyses have indicated inferior prognosis in males,[@CIT0023] possibly due to a complex association between impact of gender, age, BRAF mutational status, and primary tumor location on CRC prognosis.[@CIT0002],[@CIT0022],[@CIT0023],[@CIT0025],[@CIT0027] The inhibitory activity, documented in experimental studies, of regorafenib on mutated RAF proteins associated with poor-prognosis right-sided tumors could be an explanation of similar PFS in patients on regorafenib therapy, the observed regardless of the primary tumor site.[@CIT0003] No difference in OS between left and right has been demonstrated in the CORRELATE trial analyzing 474 patients,[@CIT0028] suggesting that regorafenib may counterbalance the negative prognostic impact that has been linked to right-sidedness of the primary tumor in mCRC.[@CIT0022]

The weak points of the present study include possible selection bias inherent to the retrospective, registry-based design, and the absence of a control cohort. Toxicity was underreported in the registry. Because regorafenib is currently used in heavily pretreated patients with mCRC, dose escalation strategy seems to be a rational approach improving safety compared to standard dosing without compromising treatment efficacy according to a recent meta-analysis.[@CIT0029],[@CIT0030] This strategy has been adopted by many clinicians and the recently published data from the prospective CORRELATE study suggest that regorafenib is initiated in nearly half of patients at a reduced dose. The median OS in that study was 7.7 months.[@CIT0028] However, this approach was not commonly used in the present cohort due to reimbursement restrictions and valid comparison of outcomes was not possible. As many patients treated with regorafenib progress early, PFS results were influenced by the interval to first restaging CT scan which was 3 months in our study contrasting with 2 months in the CORRECT trial.

Conclusion {#S0005}
==========

Outcomes of patients treated with regorafenib in the Czech real-world clinical database were superior to results reported in randomized trials, possibly due to the selection of patients with more favorable prognostic characteristics. Regorafenib is a safe and active treatment option for patients with mCRC who are progressing after other systemic therapies and maintaining good performance status.

This work was presented in part at the ESMO 2018 Congress in Munich, Germany, 19--23 October, 2018.
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[^1]: **Notes:** ^a^Including 72 patients KRAS wild-type and NRAS unknown. ^b^One patient could have more than one prior therapy. ^c^BMI at regorafenib treatment initiation is unknown in 52 patients. ^d^Site of metastases at regorafenib treatment initiation is unknown in 11 patients.

[^2]: **Abbreviations:** BMI, body-mass index; ECOG PS, Eastern Cooperative Oncology Group performance status.

[^3]: **Abbreviations:** BMI, body-mass index; ECOG PS, Eastern Cooperative Oncology Group performance status.
